PATENT CLAIM ANALYSIS

Application Number: 16039196
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "254060"]

Abstract:
Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.

Claim (Index 20):
The pharmaceutical composition of  claim 1 , wherein said pharmaceutical composition exhibits no food effect when administered to a subject.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 95.0
- Lexical Diversity: 1.53333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14623904', '14953969', '12520387', '15172478', '14528475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7898989918945076
- 35 USC 102 Novelty (BERT): 0.5539993373847751
- Combined Prediction Score: 0.7663090264435344
- Mean Citation Score: 427.776604
- Max Citation Score: 470.46823
- Similarity Product: 238.7306834174716

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test